Luminal subtypes are the most frequently diagnosed breast cancer subtypes with the most favorable treatment outcome, whereas the HER2-enriched and TNBC subtypes have worse clinical outcomes with higher propensity for metastases [81,82]. Here, ERBB2 is linked to breast carcinoma.